Icahn School of Medicine at Mount Sinai - Nash Department of Neuroscience; Icahn School of Medicine at Mount Sinai - Ronald M. Loeb Center for Alzheimer's Disease
Icahn School of Medicine at Mount Sinai - Nash Department of Neuroscience; Icahn School of Medicine at Mount Sinai - Ronald M. Loeb Center for Alzheimer's Disease
Icahn School of Medicine at Mount Sinai - Nash Department of Neuroscience; Icahn School of Medicine at Mount Sinai - Ronald M. Loeb Center for Alzheimer's Disease; Icahn School of Medicine at Mount Sinai - Department of Genetics and Genomic Sciences
Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) are clinically similar neurodegenerative movement disorders that display unique neuropathological features (i.e. Lewy body pathology and Tau pathology, respectively). While each disorder has distinct clinical and genetic risk factors, both are associated with the MAPT 17q.21.31 locus H1 haplotype. This suggests a pleiotropic effect of this genomic region. To better understand the genetic contribution of this region to these diseases, we fine-mapped the apparent pleiotropy of this locus. Our study indicates that PD and PSP are associated with different sub-haplotypes of the H1 clade. PD-associated sub-haplotypes were associated with altered LRRC37A copy number and expression, which, like other PD risk-associated genes, we hypothesize to be most relevant to astroglial function. In contrast, PSP was associated with grossly altered LD structure across the 17q21.31 locus, and risk-associated variants were found to impact chromatin structure in both neurons and microglia. We conclude that the contribution of the 17q21.31 locus to multiple disorders is a result of its structural and haplotypic complexity, which in turn impacts the regulation of multiple genes and neural cell types. This raises the possibility of novel disease-specific pathogenic mechanisms driven by 17q21.31 structural variation and altered epigenetic regulation that appear to converge on glial function and gene expression. By fine-mapping the association of H1 with PD and PSP, we have begun to untangle the apparent pleiotropy of this locus, and gain better insight into the mechanism of each disease, which will guide future functional analyses and disease models for PD and PSP.
Bowles, Kathryn and Pugh, Derian A. and Farrell, Kurt and Han, Natalia and TCW, Julia and Liu, Y. and Liang, Shiang An and Qian, Lu and Bendl, Jaroslav and Fullard, John F. and Renton, Alan E. and Casella, Alicia and Iida, Megan A. and Bandres-Ciga, Sara and Gan-Or, Ziv and Heutink, Peter and Siitonen, Ari and Bertelsen, Sarah and Karch, Celeste M. and Frucht, Steven J. and Kopell, Brian H. and Peter, Inga and Park, You Jeong and Crane, PK and Kauwe, John SK and Boehme, Kevin L. and Hoglinger, Guenter U. and Group, PART Working and Consortium (IPDGC), International Parkinson’s Disease Genomics and Consortium, Progressive Supranuclear Palsy Genetics and Charney, Alexander and Roussos, Panagiotis and Wang, JC and Poon, Wayne W. and Raj, Towfique and Crary, John F. and Goate, Alison M., 17q21.31 Sub-Haplotypes Underlying H1-Associated Risk for Parkinson's Disease and Progressive Supranuclear Palsy Converge on Altered Glial Regulation. Available at SSRN: https://ssrn.com/abstract=3518538 or http://dx.doi.org/10.2139/ssrn.3518538
This version of the paper has not been formally peer reviewed.
Subscribe to this fee journal for more curated articles on this topic
FOLLOWERS
4
PAPERS
262
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.